Mast-Cell Sarcoma

"Mast-Cell Sarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.

Descriptor ID

D012515

MeSH Number(s)

C04.557.450.565.465.124

Concept/Terms

Mast-Cell Sarcoma

Below are MeSH descriptors whose meaning is more general than "Mast-Cell Sarcoma".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Connective and Soft Tissue [C04.557.450]
Neoplasms, Connective Tissue [C04.557.450.565]
Mastocytosis [C04.557.450.565.465]
Mast-Cell Sarcoma [C04.557.450.565.465.124]

Below are MeSH descriptors whose meaning is related to "Mast-Cell Sarcoma".

Below are MeSH descriptors whose meaning is more specific than "Mast-Cell Sarcoma".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Mast-Cell Sarcoma" by people in Harvard Catalyst Profiles by year, and whether "Mast-Cell Sarcoma" was a major or minor topic of these publication.

Bar chart showing 15 publications over 9 distinct years, with a maximum of 5 publications in 1996

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1996	1	4	5
1997	1	1	2
1998	1	0	1
1999	2	0	2
2001	0	1	1
2002	0	1	1
2007	0	1	1
2012	1	0	1

Below are the most recent publications written about "Mast-Cell Sarcoma" by people in Profiles.

Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol. 2013 Apr; 26(4):533-43.

View in: PubMed
Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. J Clin Oncol. 2013 Feb 20; 31(6):e90-7.

View in: PubMed
Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites. 1989. Ocul Immunol Inflamm. 2007 May-Jun; 15(3):205-13.

View in: PubMed
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res. 2003 Aug; 27(8):677-82.

View in: PubMed
Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. J Vet Intern Med. 2003 Mar-Apr; 17(2):194-8.

View in: PubMed
Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy. Cancer Immunol Immunother. 2003 Jan; 52(1):53-8.

View in: PubMed
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001 Jul; 25(7):603-25.

View in: PubMed
Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space. Invest Ophthalmol Vis Sci. 1999 Dec; 40(13):3202-8.

View in: PubMed
Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. J Immunol. 1999 Apr 15; 162(8):4817-23.

View in: PubMed
Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J Immunol. 1998 Dec 15; 161(12):6552-8.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

J Immunol
J Biol Chem
Invest Ophthalmol Vis Sci
Biochem J
Transplantation
Leuk Res
Cancer Res
Biochem Biophys Res Commun
Int J Cancer
Biochim Biophys Acta